Patient info Search Menu

Edoxaban 60 mg film-coated tablets – patient leaflet, side effects, dosage

Updated:
Key facts
Status:
Prescription only (POM)
Medicine strength:
60 mg
Contains active substance:
ATC code:

Patient leaflet - Edoxaban 60 mg film-coated tablets

1. What Edoxaban is and what it is used for

Edoxaban contains the active substance edoxaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming. It works by blocking the activity of factor Xa, which is an important component of blood clotting.

Edoxaban is used in adults to:

  • prevent blood clots in the brain (stroke)

    and other blood vessels in the body if you have a form of irregular heart rhythm called nonvalvular atrial fibrillation and at least one additional risk factor, such as heart failure, previous stroke or high blood pressure;

  • treat blood clots in the veins of the legs

    (deep vein thrombosis) and in the blood vessels in the lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels in the legs and/or lungs.

2. What you need to know before you take Edoxaban

Do not take Edoxaban

  • if you are allergic to edoxaban or any of the

    other ingredients of this medicine (listed in section 6).

  • if you are actively bleeding;
  • if you have a disease or condition that

    increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, or recent surgery of the brain or eyes);

  • if you are taking other medicines to prevent

    blood clotting (e.g. warfarin, dabigatran, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open;

  • if you have a liver disease which leads to an

    increased risk of bleeding;

  • if you have uncontrolled high blood pressure;
  • if you are pregnant or breast feeding.

Warnings and precautions

Talk to your doctor or pharmacist before taking Edoxaban,

  • if you have an increased risk of bleeding,

    as could be the case if you have any of the following conditions:

    * endstage kidney disease or if you are on

    dialysis;

    * severe liver disease;

    * bleeding disorders;

    * a problem with the blood vessels in the

    back of your eyes (retinopathy); * recent bleeding in your brain (intracranial

    or intracerebral bleeding);

    * problems with the blood vessels in your

    brain or spinal column;

  • if you have a mechanical heart valve.

Edoxaban 15 mg is only to be used when changing from Edoxaban 30 mg to a vitamin K antagonist (e.g. warfarin) (see section 3. How to take Edoxaban).

Take special care with Edoxaban,

  • if you know that you have a disease called

    antiphospholipid syndrome (a disorder of the immune system that causes an increased risk for blood clots), tell your doctor who will decide if the treatment may need to be changed.

If you need to have an operation,

  • it is very important to take Edoxaban before

    and after the operation exactly at the times you have been told by your doctor. If possible, Edoxaban should be stopped at least 24 hours before an operation. Your doctor will determine when to restart Edoxaban.

    In emergency situations your physician will help determine the appropriate actions regarding Edoxaban.

    Children and adolescents

    Edoxaban is not recommended in children and adolescents under 18 years of age.

    Other medicines and Edoxaban

    Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

    If you are taking any of the following:

    • some medicines for fungal infections (e.g.

      ketoconazole);

    • medicines to treat abnormal heart beat (e.g.

      dronedarone, quinidine, verapamil);

    • other medicines to reduce blood

      clotting (e.g. heparin, clopidogrel or vitamin K antagonists such as warfarin, acenocoumarol, phenprocoumon or dabigatran, rivaroxaban, apixaban);

    • antibiotic medicines (e.g. erythromycin, clarithromycin);
    • medicines to prevent organ rejection after transplantation (e.g. ciclosporin);
    • anti-inflammatory and pain-relieving

      medicines (e.g. naproxen or acetylsalicylic acid);

    • antidepressant medicines called

      selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors;

If any of the above apply to you, tell your doctor before taking Edoxaban, because these medicines may increase the effects of Edoxaban and the chance of unwanted bleeding. Your doctor will decide, if you should be treated with Edoxaban and if you should be kept under observation.

If you are taking any of the following:

  • some medicines for treatment of

    epilepsy (e.g. phenytoin, carbamazepine, phenobarbital);

  • St John’s Wort, a herbal product used for anxiety and mild depression;
  • rifampicin, an antibiotic medicine.

If any of the above apply to you, tell your doctor before taking Edoxaban, because the effect of Edoxaban may be reduced. Your doctor will decide if you should be treated with Edoxaban and if you should be kept under observation.

Pregnancy and breast-feeding

Do not take Edoxaban if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Edoxaban. If you become pregnant while you are taking Edoxaban, immediately tell your doctor, who will decide how you should be treated.

Driving and using machines

Edoxaban has no or negligible effects on your ability to drive or use machines.

Edoxaban contains sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

Edoxaban contains glucose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Edoxaban

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

How much to take

The recommended dose is one 60 mg tablet once daily.

  • If you have impaired kidney function, the dose may be reduced to one 30 mg tablet once daily by your doctor;
  • if your body weight is 60 kg or lower, the recommended dose is one 30 mg tablet once daily;
  • if your doctor has prescribed

    medicines known as P-gp inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole, the recommended dose is one 30 mg tablet once daily.

How to take the tablet

Swallow the tablet, preferably with water. Edoxaban can be taken with or without food.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Edoxaban. The tablet may be crushed and mixed with water or apple puree immediately before you take it. If necessary, your doctor may also give you the crushed Edoxaban tablet through a tube via the nose (nasogastric tube) or a tube in the stomach (gastric feeding tube).

Your doctor may change your anticoagulant treatment as follows:

Changing from vitamin K antagonists (e.g. warfarin) to Edoxaban

Stop taking the vitamin K antagonist (e.g. warfarin). Your doctor will need to do blood measurements and will instruct you when to start taking Edoxaban.

Changing from non-VKA oral anticoagulants (dabigatran, rivaroxaban, or apixaban) to Edoxaban Stop taking the previous medicines (e.g. dabigatran, rivaroxaban, or apixaban) and start Edoxaban at the time of the next scheduled dose.

Page Count No. of colours

Site Barcode/ DataMatrix

Viatris SAP No.

Description

Leaflet

Edoxaban_15mg_30mg_60mg_28_10

400583095;400583097;

1 2 of 2 14-JUL-2026 18:00

Changing from parenteral anticoagulants (e.g. heparin) to Edoxaban

Stop taking the anticoagulant (e.g. heparin) and start Edoxaban at the time of the next scheduled anticoagulant dose.

Changing from Edoxaban to vitamin K antagonists (e.g. warfarin)

If you currently take 60 mg Edoxaban: Your doctor will tell you to reduce your dose of Edoxaban to a 30 mg tablet once daily and to take it together with a vitamin K antagonist (e.g. warfarin). Your doctor will need to do blood measurements and will instruct you when to stop taking Edoxaban.

If you currently take 30 mg (dose reduced) Edoxaban: Your doctor will tell you to reduce your dose of Edoxaban to a 15 mg tablet once daily and to take it together with a vitamin K antagonist (e.g. warfarin). Your doctor will need to do blood measurements and will instruct you when to stop taking Edoxaban.

Changing from Edoxaban to non-VKA oral anticoagulants (dabigatran, rivaroxaban, or apixaban)

Stop taking Edoxaban and start the non-VKA anticoagulant (e.g. dabigatran, rivaroxaban, or apixaban) at the time of the next scheduled dose of Edoxaban.

Changing from Edoxaban to parenteral anticoagulants (e.g. heparin)

Stop taking Edoxaban and start the parenteral anticoagulant (e.g. heparin) at the time of the next scheduled dose of Edoxaban.

Patients undergoing cardioversion:

If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take Edoxaban at the times your doctor tells you to prevent blood clots in the brain and other blood vessels in your body.

If you take more Edoxaban than you should

Tell your doctor immediately if you have taken too many Edoxaban tablets.

If you take more Edoxaban than recommended, you may have an increased risk of bleeding.

If you forget to take Edoxaban

You should take the tablet immediately and then continue the following day with the once daily tablet as usual. Do not take a double dose on the same day to make up for a forgotten dose.

If you stop taking Edoxaban

Do not stop taking Edoxaban without talking to your doctor first, because Edoxaban treats and prevents serious conditions.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Like other similar medicines (medicines to reduce blood clotting), Edoxaban may cause bleeding which may potentially be life-threatening. In some cases the bleeding may not be obvious.

If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your doctor immediately.

Your doctor may decide to keep you under closer observation or change your medicine.

Overall list of possible side effects:

Common (may affect up to 1 in 10 people):

  • stomach ache;
  • abnormal liver blood tests;
  • bleeding from the skin or under the skin;
  • anaemia (low levels of red blood cells);
  • bleeding from the nose;
  • bleeding from the vagina;
  • rash;
  • bleeding in the bowel;
  • bleeding from the mouth and/or throat;
  • blood found in your urine;
  • bleeding following an injury (puncture);
  • bleeding in the stomach;
  • dizziness;
  • feeling sick;
  • headache;
  • itching.

Uncommon (may affect up to 1 in 100 people):

  • bleeding in the eyes;
  • bleeding from a surgical wound following

    an operation;

  • blood in the spit when coughing;
  • bleeding in the brain;
  • other types of bleeding;
  • reduced number of platelets in your blood

    (which can affect clotting);

  • allergic reaction;
  • hives.

Rare (may affect up to 1 in 1,000 people):

  • bleeding in the muscles;
  • bleeding in joints;
  • bleeding in the abdomen;
  • bleeding in the heart;
  • bleeding inside the skull;
  • bleeding following a surgical procedure;
  • allergic shock;
  • swelling of any part of the body due to

    allergic reaction.

    Not known (frequency cannot be estimated from the available data):

    • bleeding in the kidney sometimes with presence of blood in urine leading to inability of the kidneys to work properly (anticoagulant-related nephropathy).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Edoxaban

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Edoxaban contains

The active substance is edoxaban (as tosylate monohydrate).

Each Edoxaban 15 mg film-coated tablets contains 15 mg edoxaban (as tosylate monohydrate).

Each Edoxaban 30 mg film-coated tablet contains 30 mg edoxaban (as tosylate monohydrate).

Each Edoxaban 60 mg film-coated tablet contains 60 mg edoxaban (as tosylate monohydrate).

The other excipients are:

Tablet core: Mannitol (E421),

Hydroxypropylcellulose (E463), Crospovidone (E1202), Starch, Pregelatinized (Maize), Silica, Colloidal Anhydrous (E551), Magnesium stearate (E470b).

Tablet coating: Carmellose sodium (E466), Maltodextrin, Glucose monohydrate, Lecithin (Soya)

(E322), Calcium carbonate (E170)

Edoxaban 15 mg film-coated tablets also contains: Iron Oxide Yellow (E172) and Iron Oxide Red (E172)

Edoxaban 30 mg film-coated tablets also contains: Iron Oxide Red (E172)

Edoxaban 60 mg film-coated tablets also contains: Iron Oxide Yellow (E172)

What Edoxaban looks like and contents of the pack

Edoxaban 15 mg film-coated tablets are orange, round-shaped film-coated tablets debossed with “15” on one side and plain on the other side, with a diameter of 6.6 mm ± 5 %.

Edoxaban 30 mg film-coated tablets are pink, round-shaped film-coated tablets debossed with “30” on one side and plain on the other side, with a diameter of 8.4 mm ± 5 %.

Edoxaban 60 mg film-coated tablets are yellow, round-shaped film-coated tablets debossed with “60” on one side and plain on the other side, with a diameter of 10.4 mm ± 5 %.

Each pack of Edoxaban 15 mg

contains 10 tablets in transparent, colourless aluminium foil blisters.

Each pack of Edoxaban 30 mg and 60 mg contains 28, 30 or 100 tablets in transparent, colourless aluminium foil blisters.

Each pack of Edoxaban 30 mg and 60 mg contains 28, 30 or 100 tablets in transparent, colourless aluminium foil calendar blisters.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Viatris,

Station Close,

Potters Bar,

EN6 1TL,

United Kingdom.

Manufacturer

PHAROS MT Limited

Hf62x, Qasam Industrijali Hal Far, Hal Far, Birzebbuga, BBG 3000, Malta

Or

Pharos Pharmaceutical Oriented Services Ltd. Lesvou Street End, Thesi Loggos Industrial Zone, Metamorfossi, 144 52, Greece

This leaflet was last revised in July 2026.

Page Count

No. of colours

Site Barcode/ DataMatrix

Viatris SAP No.

Description

Patient Alert Card

PL 04569/1904, PL 04569/1905,

PPAC02-028.00

PRS PAC04_351.5x34_4-Panel

Edoxaban_15mg_30mg_60mg_20_28

400583095;400583097;

1 1 of 2

11-JUL-2026 07:00

Info

FRONT

However, a calibrated anti-Factor Xa assay may help inform clinical decisions. Please consult the Summary of Product Characteristics (SmPC) for more information.

ABOUT YOUR TREATMENT

You have been prescribed Edoxaban, an anticoagulant medicine, which thins your blood and helps prevent you from suffering blood clots. It is important that you take your medicine exactly as instructed by your doctor. If you miss a dose, take it immediately and then continue the following day as normal – do not take

double the prescribed dose in a single day. Do not start any other medications (including over the counter) without consulting your doctor. Do not stop taking Edoxaban without consulting your doctor as this can increase your risk of developing a blood clot. Please read the Patient Information Leaflet found inside each pack of Edoxaban.

WHEN TO SEEK MEDICAL ADVICE – RISK OF BLEEDING Taking an anticoagulant medicine such as Edoxaban can increase your risk of bleeding. It is therefore important to be aware of the

possible signs and symptoms of bleeding and to speak to your doctor immediately if you experience any of the following: bruising or bleeding under the skin, blood in the urine, coughing up blood, vomiting blood or material that looks like ground coffee, nose bleeds or cuts that take a long time to stop bleeding, tar-coloured stools, dizziness or sudden headache, unexplained tiredness, abnormal vaginal bleeding, including heavier or prolonged menses Please talk to your doctor if you experience any unusual symptoms.

PATIENT ALERT CARD

Edoxaban film-coated tablets

Please keep this card with you at all times.

Present it to your healthcare professional, pharmacist, surgeon or dentist before any medical treatment or intervention.

PPAC02-028.00

Page Count No. of colours

Site Barcode/ DataMatrix

Viatris SAP No. Description

Patient Alert Card

PL 04569/1904, PL 04569/1905,

PPAC02-028.00

PRS PAC04_351.5x34_4-Panel Edoxaban_15mg_30mg_60mg_20_28

400583095;400583097;

1 2 of 2 11-JUL-2026 07:00

Info

BACK

TREATMENT INFORMATION (To be completed by physician) Edoxaban has been prescribed at a once-daily dose of: mg

Started on: / (mm/yy)

Blood type:

Other medicines/conditions:

PRESCRIBER INFORMATION

For more information or in case of emergency, please contact:

Physician’s name:

Phone number, practice stamp:

Signature of physician:

INFORMATION FOR HEALTHCARE PROFESSIONALS

Edoxaban is an oral anticoagulant factor Xa inhibitor. When an invasive procedure is required, Edoxaban should be stopped at least 24 hours beforehand, and appropriate caution exercised. Edoxaban may increase the risk of bleeding. In case of clinically significant bleeding, stop treatment immediately. Coagulation tests such as international normalised ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (aPTT) are not a useful measure of the effect of Edoxaban.

PATIENT INFORMATION

Patient name:

Date of birth:

In case of emergency, please contact:

Phone no:

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 04569/1906

Last revision stated in the text: July 2026 · MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Edoxaban 60 mg film-coated tablets

What these facts mean

Prescription needed?? Yes, prescription-only medicine (POM)
Active substance? Edoxaban
Strength? 60 mg
Pharmaceutical form? Oral tablet
Yellow, round, bi-convex film coated tablets, with a breakline on one side measuring approximately 10.5 mm
The tablet can be divided into equal doses.
How is it taken? Oral
Excipients? Lactose monohydrate, Starch, pregelatinized, Sodium starch glycolate, Hydroxypropyl cellulose (E463), Magnesium stearate (E470b)., Hypromellose (E464), Titanium dioxide (E171), Macrogol, Talc (E553b), Iron oxide yellow (E172)
Is it available?? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 2 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC)? Antithrombotic agents, direct factor Xa inhibitors
  1. B Blood and blood forming organ drugs
    1. B01 Antithrombotic agents
      1. B01A Antithrombotic agents
        1. B01AF Direct factor Xa inhibitors
          1. B01AF03 edoxaban
Marketing authorisation? PL 04569/1906, PL 53835/0074 (first authorised 13 April 2026)
Marketing authorisation holder? Celix Pharma Ltd
Codes? BNF 02080200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.